Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.

Trial Details

NCT ID
NCT06239727
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • PD-1 blocking antibody
  • Gemcitabine
  • Cisplatin (80 mg/m2)
  • Reduced-dose Intensity-modulated radiotherapy
  • Conventional-dose Intensity-modulated radiotherapy
  • Cisplatin (100 mg/m2)
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Xiamen, Fujian, China|24.47979,118.08187
  • Dongguan, Guangdong, China|23.01797,113.74866
  • Foshan, Guangdong, China|23.02677,113.13148
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age: 18 Years to 65 Years;
  • Eastern Cooperative Oncology Group performance status ≤1;
  • Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;
  • Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →